CA AB1751

Extends requirement for prescribers to discuss opioid risks, mental health/substance abuse disorder interactions, benzodiazepine/alcohol/CNS depressant dangers, and availability of nonpharmacological pain treatments to all patients, not just minors, before issuing first opioid prescription in a single course of treatment.

Removes exception for patients with chronic intractable pain diagnosis and replaces it with exception only for patients currently receiving hospice care.

Requires prescribers to obtain written patient consent (or parent/guardian consent for minors) documenting the controlled substance name, quantity, initial dose, and certification that required discussions occurred.

Defines "nonpharmacological treatments for pain" to include acupuncture, chiropractic care, physical therapy, occupational therapy, and licensed mental health provider services.

Clarifies that noncompliance does not constitute a criminal offense and does not require health insurers to change existing coverage for nonpharmacological treatments.